Skip to main content
Top
Published in: BMC Infectious Diseases 1/2016

Open Access 01-12-2016 | Research article

The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review

Authors: Rebecca C. Harris, Louis Grandjean, Laura J. Martin, Alexander J. P. Miller, Joseph-Egre N. Nkang, Victoria Allen, Mishal S. Khan, Katherine Fielding, David A. J. Moore

Published in: BMC Infectious Diseases | Issue 1/2016

Login to get access

Abstract

Background

Globally it is estimated that 480 000 people developed multidrug-resistant tuberculosis (MDR-TB) in 2014 and 190 000 people died from the disease. Successful treatment outcomes are achieved in only 50 % of patients with MDR-TB, compared to 86 % for drug susceptible disease. It is widely held that delay in time to initiation of treatment for MDR-TB is an important predictor of treatment outcome. The objective of this review was to assess the existing evidence on the outcomes of multidrug- and extensively drug-resistant tuberculosis patients treated early (≤4 weeks) versus late (>4 weeks) after diagnosis of drug resistance.

Methods

Eight sources providing access to 17 globally representative electronic health care databases, indexes, sources of evidence-based reviews and grey literature were searched using terms incorporating time to treatment and MDR-TB. Two-stage sifting in duplicate was employed to assess studies against pre-specified inclusion and exclusion criteria. Only those articles reporting WHO-defined treatment outcomes were considered for inclusion. Articles reporting on fewer than 10 patients, published before 1990, or without a comparison of outcomes in patient groups experiencing different delays to treatment initiation were excluded.

Results

The initial search yielded 1978 references, of which 1475 unique references remained after removal of duplicates and 28 articles published pre-1990. After title and abstract sifting, 64 papers underwent full text review. None of these articles fulfilled the criteria for inclusion in the review.

Conclusions

Whilst there is an inherent logic in the theory that treatment delay will lead to poorer treatment outcomes, no published evidence was identified in this systematic review to support this hypothesis. Reports of programmatic changes leading to reductions in treatment delay exist in the literature, but attribution of differences in outcomes specifically to treatment delay is confounded by other contemporaneous changes. Further primary research on this question is not considered a high priority use of limited resources, though where data are available, improved reporting of outcomes by time to treatment should be encouraged.
Appendix
Available only for authorised users
Literature
1.
go back to reference Global Tuberculosis Report 2015. Geneva: World Health Organisation; 2015. Global Tuberculosis Report 2015. Geneva: World Health Organisation; 2015.
2.
go back to reference Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organisation; 2011. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organisation; 2011.
3.
go back to reference Van Deun A et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684–92.CrossRefPubMed Van Deun A et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684–92.CrossRefPubMed
4.
go back to reference Moher D et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9. w64.CrossRefPubMed Moher D et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9. w64.CrossRefPubMed
5.
go back to reference Richardson WS et al. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123(3):A12–3.PubMed Richardson WS et al. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123(3):A12–3.PubMed
6.
go back to reference Haynes RBSDL, Guyatt GH, Tugwell PS. Clinical epidemiology: how to do clinical practice research. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2006. Haynes RBSDL, Guyatt GH, Tugwell PS. Clinical epidemiology: how to do clinical practice research. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
7.
go back to reference Laserson KF, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9(6):640–5.PubMed Laserson KF, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9(6):640–5.PubMed
8.
go back to reference Yu MC, et al. Characteristics and treatment outcomes of MDR tuberculosis in Taiwan. Int J Infect Dis. 2014;21(Supplement 1):57. Yu MC, et al. Characteristics and treatment outcomes of MDR tuberculosis in Taiwan. Int J Infect Dis. 2014;21(Supplement 1):57.
9.
go back to reference Mukherjee JS, et al. Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients from lima, Peru. Int J Tuberc Lung Dis. 2003;7(7):637–44.PubMed Mukherjee JS, et al. Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients from lima, Peru. Int J Tuberc Lung Dis. 2003;7(7):637–44.PubMed
10.
go back to reference Javia A, et al. Clinical profile of MDR-TB patients and their early response to DOTS PLUS: An Indian perspective. Eur Respir J. 2013;42(Suppl 57). Javia A, et al. Clinical profile of MDR-TB patients and their early response to DOTS PLUS: An Indian perspective. Eur Respir J. 2013;42(Suppl 57).
11.
go back to reference Loveday M, et al. Community-based care vs. Centralised hospitalisation for MDRTB patients, KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2015;9(2):163–71.CrossRef Loveday M, et al. Community-based care vs. Centralised hospitalisation for MDRTB patients, KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2015;9(2):163–71.CrossRef
12.
13.
go back to reference Van Der Walt M, et al. Culture conversion rates of multidrug resistant (MDRTB) patients treated in the community versus an inpatient setting in a rural area of the Western Cape (WC) of South Africa. Eur Respir J. 2012;40(Suppl 56). Van Der Walt M, et al. Culture conversion rates of multidrug resistant (MDRTB) patients treated in the community versus an inpatient setting in a rural area of the Western Cape (WC) of South Africa. Eur Respir J. 2012;40(Suppl 56).
14.
go back to reference Garcia-Garcia Ma DL, et al. Drug resistance of Mycobacterium tuberculosis in Orizaba, Veracruz. Implications for the tuberculosis prevention and control program. Rev Investig Clin. 2001;53(4):315–23. Garcia-Garcia Ma DL, et al. Drug resistance of Mycobacterium tuberculosis in Orizaba, Veracruz. Implications for the tuberculosis prevention and control program. Rev Investig Clin. 2001;53(4):315–23.
15.
go back to reference Dave P, et al. Has introduction of rapid drug susceptibility testing at diagnosis impacted treatment outcomes among previously treated tuberculosis patients in Gujarat, India? PLoS One. 2015;10(4):e0121996.CrossRefPubMedPubMedCentral Dave P, et al. Has introduction of rapid drug susceptibility testing at diagnosis impacted treatment outcomes among previously treated tuberculosis patients in Gujarat, India? PLoS One. 2015;10(4):e0121996.CrossRefPubMedPubMedCentral
16.
go back to reference Ahmad N, et al. Management and treatment outcomes of MDR-TB: Results froma setting with high rates of drug resistance. Int J Tuberc Lung Dis. 2015;19(9):1109–14.CrossRefPubMed Ahmad N, et al. Management and treatment outcomes of MDR-TB: Results froma setting with high rates of drug resistance. Int J Tuberc Lung Dis. 2015;19(9):1109–14.CrossRefPubMed
17.
go back to reference Mukherjee JS, et al. New challenges in the clinical management of drug-resistant tuberculosis. Infect Dis Clin Pract. 2002;11(6):329-339. Mukherjee JS, et al. New challenges in the clinical management of drug-resistant tuberculosis. Infect Dis Clin Pract. 2002;11(6):329-339.
18.
go back to reference Satti H, et al. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho. PLoS One. 2012;7(10):e46943.CrossRefPubMedPubMedCentral Satti H, et al. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho. PLoS One. 2012;7(10):e46943.CrossRefPubMedPubMedCentral
19.
go back to reference Handayani D, et al. Profile and treatment outcome of extensive drug resistant tuberculosis (XDR-TB) patients in Persahabatan Hospital, Jakarta Indonesia. Respirology. 2013;18: 3–4. doi: 10.1111/resp.12183_2. Handayani D, et al. Profile and treatment outcome of extensive drug resistant tuberculosis (XDR-TB) patients in Persahabatan Hospital, Jakarta Indonesia. Respirology. 2013;18: 3–4. doi: 10.​1111/​resp.​12183_​2.
20.
go back to reference Drobniewski FA, Balabanova YM. The diagnosis and management of multiple-drug-resistant tuberculosis at the beginning of the new millenium. Int J Infect Dis. 2002;6(1):S21–31.CrossRefPubMed Drobniewski FA, Balabanova YM. The diagnosis and management of multiple-drug-resistant tuberculosis at the beginning of the new millenium. Int J Infect Dis. 2002;6(1):S21–31.CrossRefPubMed
21.
go back to reference Migliori GB, et al. The XDR-TB emergency: Answers from the scientific community. Rassegna di Patologia dell’Apparato Respiratorio. 2009;24(5):319-24. Migliori GB, et al. The XDR-TB emergency: Answers from the scientific community. Rassegna di Patologia dell’Apparato Respiratorio. 2009;24(5):319-24.
22.
go back to reference Otero L, et al. Time to initiation of multidrug-resistant tuberculosis treatment and its relation with outcome in a high incidence district in Lima, Peru. Trop Med Int Health. 2015;20(3):322–5.CrossRefPubMed Otero L, et al. Time to initiation of multidrug-resistant tuberculosis treatment and its relation with outcome in a high incidence district in Lima, Peru. Trop Med Int Health. 2015;20(3):322–5.CrossRefPubMed
23.
go back to reference Milanov V, et al. Treatment outcome and factors associated with unfavourable treatment results in cases with multidrug-resistant tuberculosis in Bulgaria for the period 2009-2010. Eur Respir J. 2012;4(2):131-7. Milanov V, et al. Treatment outcome and factors associated with unfavourable treatment results in cases with multidrug-resistant tuberculosis in Bulgaria for the period 2009-2010. Eur Respir J. 2012;4(2):131-7.
24.
go back to reference Doh HK, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008;178(10):1075–82.CrossRef Doh HK, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008;178(10):1075–82.CrossRef
26.
go back to reference Isaakidis P, et al. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2015;19(8):969–78.CrossRefPubMed Isaakidis P, et al. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2015;19(8):969–78.CrossRefPubMed
27.
go back to reference Marks SM, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg Infect Dis. 2014;20(5):812–21.CrossRefPubMedPubMedCentral Marks SM, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg Infect Dis. 2014;20(5):812–21.CrossRefPubMedPubMedCentral
28.
go back to reference Leimane V, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365(9456):318–26.CrossRefPubMed Leimane V, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365(9456):318–26.CrossRefPubMed
29.
go back to reference Mitnick C, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima. Peru N Engl J Med. 2003;348(2):119–28.CrossRefPubMed Mitnick C, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima. Peru N Engl J Med. 2003;348(2):119–28.CrossRefPubMed
30.
go back to reference Schaaf HS, Shean K, Donald PR. Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. Arch Dis Child. 2003;88(12):1106–11.CrossRefPubMedPubMedCentral Schaaf HS, Shean K, Donald PR. Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. Arch Dis Child. 2003;88(12):1106–11.CrossRefPubMedPubMedCentral
31.
go back to reference Dheda K, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375(9728):1798–807.CrossRefPubMed Dheda K, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375(9728):1798–807.CrossRefPubMed
32.
go back to reference Kim H-R, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45(10):1290–5.CrossRefPubMed Kim H-R, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45(10):1290–5.CrossRefPubMed
33.
go back to reference Geerligs WA, et al. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis. 2000;4(8):758–64.PubMed Geerligs WA, et al. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis. 2000;4(8):758–64.PubMed
34.
go back to reference Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis. 1998;2(11):877–84.PubMed Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis. 1998;2(11):877–84.PubMed
35.
go back to reference Flament-Saillour M, et al. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case–control study. Am J Respir Crit Care Med. 1999;160(2):587–93.CrossRefPubMed Flament-Saillour M, et al. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case–control study. Am J Respir Crit Care Med. 1999;160(2):587–93.CrossRefPubMed
36.
go back to reference Keshavjee S, et al. Treating multidrug-resistant tuberculosis in Tomsk, Russia. Ann N Y Acad Sci. 2008;1136(1):1–11.CrossRefPubMed Keshavjee S, et al. Treating multidrug-resistant tuberculosis in Tomsk, Russia. Ann N Y Acad Sci. 2008;1136(1):1–11.CrossRefPubMed
37.
go back to reference Chan ED, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004;169(10):1103–9.CrossRefPubMed Chan ED, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004;169(10):1103–9.CrossRefPubMed
38.
go back to reference Goble M, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328(8):527–32.CrossRefPubMed Goble M, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328(8):527–32.CrossRefPubMed
39.
go back to reference Keshavjee S, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008;372(9647):1403–9.CrossRefPubMed Keshavjee S, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008;372(9647):1403–9.CrossRefPubMed
40.
go back to reference Wood AJJ, Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993;329(11):784–91.CrossRef Wood AJJ, Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993;329(11):784–91.CrossRef
41.
go back to reference Leimane V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004. Eur Respir J. 2010;36(3):584–93.CrossRefPubMed Leimane V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004. Eur Respir J. 2010;36(3):584–93.CrossRefPubMed
42.
go back to reference Ettehad D, et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(6):449–56.CrossRefPubMed Ettehad D, et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(6):449–56.CrossRefPubMed
43.
go back to reference Orenstein EW, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(3):153–61.CrossRefPubMed Orenstein EW, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(3):153–61.CrossRefPubMed
44.
go back to reference Kwon YS, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis. 2008;47(4):496–502.CrossRefPubMed Kwon YS, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis. 2008;47(4):496–502.CrossRefPubMed
45.
go back to reference Heller T, et al. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2010;14(4):420–6.PubMed Heller T, et al. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2010;14(4):420–6.PubMed
46.
go back to reference Loveday M, et al. Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2012;16(2):209–15.CrossRefPubMedPubMedCentral Loveday M, et al. Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2012;16(2):209–15.CrossRefPubMedPubMedCentral
47.
go back to reference Shin SS, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med. 2010;182(3):426–32.CrossRefPubMedPubMedCentral Shin SS, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med. 2010;182(3):426–32.CrossRefPubMedPubMedCentral
48.
go back to reference Mpagama SG, et al. Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania. PLoS One. 2013;8(5):e62034.CrossRefPubMedPubMedCentral Mpagama SG, et al. Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania. PLoS One. 2013;8(5):e62034.CrossRefPubMedPubMedCentral
49.
go back to reference Zhang X et al. Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study. Tropical Med Int Health. 2015;20(11):1431–7.CrossRef Zhang X et al. Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study. Tropical Med Int Health. 2015;20(11):1431–7.CrossRef
50.
go back to reference Chan P-C, et al. Effectiveness of a government-organized and hospital-initiated treatment for multidrug-resistant tuberculosis patients--a retrospective cohort study. PLoS One. 2013;8(2):e57719.CrossRefPubMedPubMedCentral Chan P-C, et al. Effectiveness of a government-organized and hospital-initiated treatment for multidrug-resistant tuberculosis patients--a retrospective cohort study. PLoS One. 2013;8(2):e57719.CrossRefPubMedPubMedCentral
51.
go back to reference Li R, et al. Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: a before-and-after study. Lancet Global Health. 2015;3(4):e217–28.CrossRefPubMed Li R, et al. Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: a before-and-after study. Lancet Global Health. 2015;3(4):e217–28.CrossRefPubMed
52.
go back to reference Seddon JA, et al. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax. 2014;69(5):458–64.CrossRefPubMed Seddon JA, et al. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax. 2014;69(5):458–64.CrossRefPubMed
53.
go back to reference Gandhi NR, et al. HIV coinfection in multidrug-and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181(1):80–6.CrossRefPubMed Gandhi NR, et al. HIV coinfection in multidrug-and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181(1):80–6.CrossRefPubMed
54.
go back to reference Velásquez GE, et al. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis. 2014;59(1):9–15.CrossRefPubMedPubMedCentral Velásquez GE, et al. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis. 2014;59(1):9–15.CrossRefPubMedPubMedCentral
55.
go back to reference Gegia M, et al. Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009–2011. Int J Tuberc Lung Dis. 2013;17(5):624–9.CrossRefPubMedPubMedCentral Gegia M, et al. Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009–2011. Int J Tuberc Lung Dis. 2013;17(5):624–9.CrossRefPubMedPubMedCentral
56.
go back to reference Schnippel K, et al. Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register. Int J Infect Dis. 2015;39:89–94.CrossRefPubMed Schnippel K, et al. Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register. Int J Infect Dis. 2015;39:89–94.CrossRefPubMed
57.
go back to reference Mohr E, et al. Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa. Trans R Soc Trop Med Hyg. 2015;109(7):425–32.CrossRefPubMed Mohr E, et al. Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa. Trans R Soc Trop Med Hyg. 2015;109(7):425–32.CrossRefPubMed
58.
go back to reference Mirsaeidi SM, et al. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. Int J Infect Dis. 2005;9(6):317–22.CrossRefPubMed Mirsaeidi SM, et al. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. Int J Infect Dis. 2005;9(6):317–22.CrossRefPubMed
59.
go back to reference Jeon DS, et al. Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector. J Korean Med Sci. 2011;26(1):33–41.CrossRefPubMed Jeon DS, et al. Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector. J Korean Med Sci. 2011;26(1):33–41.CrossRefPubMed
60.
go back to reference Charles M, et al. Treatment outcomes for patients with multidrug-resistant tuberculosis in post-earthquake Port-au-Prince, Haiti. AmJTrop Med Hyg. 2014;91(4):715–21.CrossRef Charles M, et al. Treatment outcomes for patients with multidrug-resistant tuberculosis in post-earthquake Port-au-Prince, Haiti. AmJTrop Med Hyg. 2014;91(4):715–21.CrossRef
61.
go back to reference Helbling P, et al. Treatment outcomes of multidrug-resistant tuberculosis in Switzerland. Swiss Med Wkly. 2014;144:w14053.PubMed Helbling P, et al. Treatment outcomes of multidrug-resistant tuberculosis in Switzerland. Swiss Med Wkly. 2014;144:w14053.PubMed
62.
go back to reference Drobac PC, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics. 2006;117(6):2022–9.CrossRefPubMed Drobac PC, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics. 2006;117(6):2022–9.CrossRefPubMed
63.
go back to reference Cox H, et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis. 2014;18(4):441–8.CrossRefPubMed Cox H, et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis. 2014;18(4):441–8.CrossRefPubMed
64.
go back to reference Seddon JA, et al. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis. 2012;54(2):157–66.CrossRefPubMed Seddon JA, et al. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis. 2012;54(2):157–66.CrossRefPubMed
65.
go back to reference Piubello A, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014;18(10):1188–94.CrossRefPubMed Piubello A, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014;18(10):1188–94.CrossRefPubMed
66.
go back to reference Bonilla CA, et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One. 2008;3(8):e2957.PubMedPubMedCentral Bonilla CA, et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One. 2008;3(8):e2957.PubMedPubMedCentral
67.
go back to reference Singla R, et al. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis. 2009;13(8):976–81.PubMed Singla R, et al. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis. 2009;13(8):976–81.PubMed
68.
go back to reference Kipiani M, et al. Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59(11):1559–66.CrossRefPubMedPubMedCentral Kipiani M, et al. Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59(11):1559–66.CrossRefPubMedPubMedCentral
69.
go back to reference Holtz TH, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med. 2006;144(9):650–9.CrossRefPubMed Holtz TH, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med. 2006;144(9):650–9.CrossRefPubMed
70.
go back to reference Park JK, et al. Treatment outcomes and prognostic factors in patients with multidrug-resistant tuberculosis in Korean private hospitals. Tuberc Respir Dis. 2010;69(2):95–102.CrossRef Park JK, et al. Treatment outcomes and prognostic factors in patients with multidrug-resistant tuberculosis in Korean private hospitals. Tuberc Respir Dis. 2010;69(2):95–102.CrossRef
71.
go back to reference Kranzer K, et al. The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review. Int J Tuberc Lung Dis. 2013;17(4):432–46.CrossRefPubMed Kranzer K, et al. The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review. Int J Tuberc Lung Dis. 2013;17(4):432–46.CrossRefPubMed
Metadata
Title
The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review
Authors
Rebecca C. Harris
Louis Grandjean
Laura J. Martin
Alexander J. P. Miller
Joseph-Egre N. Nkang
Victoria Allen
Mishal S. Khan
Katherine Fielding
David A. J. Moore
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-1524-0

Other articles of this Issue 1/2016

BMC Infectious Diseases 1/2016 Go to the issue